Sign in
Stories
Cancer Vaccine Breakthrough Revealed
Share
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
Adagene Advances Clinical Collaboration
Cue Biopharma to Present Corporate Updat...
Egle Therapeutics Bolsters Leadership Te...
FDA Investigates CAR T Therapies
Overview
API
IO Biotech's abstract on cancer vaccine accepted for AACR Annual Meeting, highlighting immune resistance pathways. CEO emphasizes dual antigen vaccine potential. Phase 3 and 2 trials underway in collaboration with Merck.
Ask a question
How might the findings from the abstract influence future cancer treatment strategies?
In what ways could this breakthrough collaboration impact the broader pharmaceutical industry?
What specific challenges might IO Biotech face in advancing the vaccine to market?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage